AAD 2019—Risankizumab superior to adalimumab in moderate-to-severe psoriasis


  • Marielle Fares, Pharm.D.
  • Conference Reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The phase 3 IMMvent trial indicated that continuous treatment with risankizumab, an IL-23 inhibitor, is safe and superior to adalimumab in the treatment of moderate-to-severe psoriasis.
  • Patients who were switched from adalimumab to risankizumab also showed superior benefit compared with those who continued adalimumab therapy.

Why this matters

  • IL-23 plays key role in the pathogenesis and maintenance of plaque psoriasis.
  • Intermediate and nonresponders to adalimumab should be considered for risankizumab therapy.

Key results

  • Risankizumab resulted in significantly greater efficacy than adalimumab as measured by Psoriasis Area and Severity Index (PASI) 90, static Physician's Global Assessment clear or almost clear (sPGA 0/1), and Dermatology Life Quality Index (DLQI) scores, at weeks 16 and 44 (P<.001 for all>
  • Week 16 PASI90 (72.4% vs 47.4%) and sPGA 0/1 (83.7% vs 60.2%).
  • Week 44 PASI90 (66% vs 21.4%) and sPGA 0/1 (73.6% vs 33.9%).
  • The proportion of patients achieving PASI90 or absolute PASI and DLQI 0/1 was significantly higher in the risankizumab groups (at the beginning of the study and in switchers) than in the adalimumab group.
  • Patients who were switched to risankizumab at week 16 had significantly greater efficacy results when compared with patients who continued on adalimumab.
  • Treatment-emergent adverse events were similar across all groups.
  • No new adverse events were reported after long-term risankizumab.
  • Study design

    • 605 patients were randomly assigned 1:1 to receive risankizumab or adalimumab for 16 weeks (part A).
    • At week 16, patients with intermediate response to adalimumab (as measured by PASI) were randomly assigned 1:1 to receive risankizumab or continue adalimumab (part B).
    • Funding: AbbVie, Inc. and Boehringer Ingelheim Pharmaceuticals.

    Limitations

    • None.
       

    Please confirm your acceptance

    To gain full access to GPnotebook please confirm:

    By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

    Submit